Effect of parasitism and PDV injection on lipid droplet size in the fat body of FAW larvae. حسب Xian Li (201841)

pI7L suppresses the IFN-γ-triggered JAK-STAT signaling pathway. حسب Meilin Li (1832905)

The <i>I7L</i> gene is involved in ASFV pathogenicity in pigs. حسب Meilin Li (1832905)

Changes in circulatory variables during CPB. حسب Vincent Pey (21433304)

The biological characteristics of the I7L protein (pI7L). حسب Meilin Li (1832905)

Effect of <i>CrBV3-31</i> interference on lipid metabolism in FAW larvae. حسب Xian Li (201841)

Annual number of outpatient visits in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

Annual number of outpatient visits in all eyes. حسب Yasuyuki Sotani (20114144)

"…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"

Time course of best-corrected visual acuity (BCVA) in all eyes. حسب Yasuyuki Sotani (20114144)

pI7L suppresses the IFN-<i>γ</i>-triggered JAK-STAT signaling pathway. حسب Meilin Li (1832905)

Annual treatment frequencies in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…<p>In the recurrence group, the respective treatment counts for anti-VEGF, STTA, MA-PC, PPV, and total treatments (mean ± standard deviation) in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …"

Time course of central retinal thickness (CRT) in all eyes. حسب Yasuyuki Sotani (20114144)

"…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"

pI7L inhibits the phosphorylation of STAT1 depending on its tyrosine at position 98. حسب Meilin Li (1832905)

Annual treatment frequencies in all eyes. حسب Yasuyuki Sotani (20114144)

"…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…"

Effect of <i>CrBV3-31</i> interference on the performance of <i>Cotesia ruficrus</i> offspring. حسب Xian Li (201841)

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …"

iBAT characterization of the <i>aP2-Drp1</i>^f/f neonatal mice. حسب Yuta Ibayashi (20404811)

African catfish intervention sites, snail sampling sites and local primary schools in Chifunfu (A), Kahumulo (B) and Sweya (C). حسب Roland Proud (11764892)

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…Regarding the mean number of treatments in the recurrence group, anti-VEGF, STTA, MA-PC, PPV, and total treatment counts in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …"

Conceptual diagram of survival curve and loss of life expectancy. حسب Hiroaki Saito (24514)